The new technic of producing antibodies seems to save millions of dollar and to improve the reproductibility Antibodies, also called immunoglobulins, are large Y-shaped proteins which function to identify and help remove foreign antigens or targets such as viruses and bacteria. In the human body those antibodies are used to identify and attac a antigen, being part of the immune system. Those antibodies(the monoclonal ones) has been for years use as a form of immunotherapy. This immunotherapy consists on using monoclonal antibodies (mAb) to specifically bind to target antigens that could be cells or proteins. The main objective is stimulating the patient’s immune system to attack the malignant tumor cells and the prevention of tumor growth by blocking specific cell receptors. Monoclonal antibodies are used for the treatment of autoimmune diseases including rheumatoid arthritis, Crohn’s disease and ulcerative Colitis But another interesting use of the antibodies is in the lab. The scientist have been using antibodies to track proteins of interest because they are able to create binding to specific targets, becoming an essential lab tool. Even thought the antibodies are indispensable in biology and science , scientist have noticed that monoclonal antibodies have deficits. Andrew Bradbury of the Los Alamos National Labs, USA, and Andreas Plückthun of the Department of Biochemistry of the University of Zürich have consist that the quality of the antibodies used on labs nowadays is insufficient for researches. The monoclonal antibody is made by fusing a normal antibody with a cancer cell ,which produce a Hybridoma. Is this hybridoma that produce the monoclonal antibodies.The problem of those monoclonal antibodies is that the hybridoma cell lines can die off,lose their antibodies genes or stop growing when it is a change of temperature. This cause the losing of the particular antibody.. This deficit of the monoclonal antibodies , is calculated to bring lots of waste in time and money.Only the half of 6000 tested antibodies recognize their target protein, which brings to waste every year about 350 Mio $ by this useless antibodies. This problem seems to be solved with a new technique of preparing the monoclonal antibodies,which is the Recombinate DNA technology. The key of this new technique proposed by Plückthun stays on knowing the DNA structure of a determinate antibody. When you know the DNA of specific antibody, everyone in the world can regenerate it. Therapeutic antibodies are all made from recombinant DNA and this is the reason they are extremely well characterized and have a high quality. Plückthun advise that the first thing to do is investing in researches based on the efficient technology of recombinant binding reagents. In fact they aren’t cheaper to produce than the classical monoclonal antibodies(those obtained by the hybridoma), but they have a better potential throught new technologies and are more efficient. This new technology of producing the antibodies will save lots of money and will improve the reproductibility , that affect a lot the researches. Its seems in 10 years we can say ‘’ADIOS PARASIEMPRE’- ‘GOODBYE FOREVER’ to all the problems caused by poorly characterized monoclonal antibodies.

Leave a Reply